Klow Blend
BPC-157 + TB-500 + KPV + GHK-Cu
In short
- BPC-157 plus TB-500 plus KPV plus GHK-Cu — the Glow blend with KPV added for inflammation.
- KPV is a C-terminal fragment of alpha-MSH studied for anti-inflammatory effects. It is NOT a potassium channel opener; the library description previously said so and has been corrected.
- Four components means four unknowns and no way to attribute anything to anything.
- Carries the same copper consideration as Glow, plus a fourth compound with no human data.
- Prohibited in sport, because TB-500 is explicitly prohibited at all times.
Structure
A blend of four peptides. See the BPC-157, TB-500, KPV and GHK-Cu entries for their individual structures.
How it works
BPC-157 and TB-500 supply the repair rationale; GHK-Cu the copper-peptide dermal rationale; KPV the anti-inflammatory one.
KPV appears to act intracellularly, inhibiting NF-kB activation and reducing transcription of inflammatory cytokines, and it largely lacks the melanocortin receptor activity responsible for pigmentation in alpha-MSH analogues.
The four-way rationale is repair plus skin plus inflammation. It is a reasonable-sounding assembly of individually plausible mechanisms, and nothing has tested it.
What the research shows
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually.
GHK-Cu has controlled topical human evidence. The other three have no human efficacy evidence — KPV has none at all, BPC-157 has three small pilots, and TB-500's fragment has none.
The four-component combination has never been studied in any species.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
No published dosing data for this compound.
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported combined daily dosing | Drawn to deliver roughly 250 µg BPC-157, 400 µg TB-500, 250 µg KPV, 800 µg GHK-Cu | subcutaneous |
No study has tested this specific combination in humans. Whatever evidence exists belongs to the individual components, tested individually. A pre-mixed vial fixes the ratio between components at whatever the vendor chose. You can change the total volume you draw, but you cannot change the proportions — so if one component suits you at a different relative amount, a blend cannot express that. Buying components separately costs more vials and buys back that control. With four components the fixed-ratio problem compounds — the vial encodes one set of proportions for four compounds whose conventional protocols run on different schedules and, for two of them, different routes entirely. KPV's preclinical work is oral for gut applications, and GHK-Cu's human evidence is topical.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
The solution is blue from the copper component. Subcutaneous injection is the community route.
Worth noting that two of the four components have their evidence on other routes — KPV orally for gut inflammation, GHK-Cu topically for skin — so injecting the blend takes both away from the route their research used.
Side effects
Injection-site irritation is commonly reported, attributable mainly to the copper peptide.
The copper-load consideration from GHK-Cu applies: copper has a narrow safe range and repeated injection of a copper complex is uncharacterised. Wilson disease or any copper-handling disorder is a clear contraindication for systemic use.
Three of the four components are associated with angiogenesis or cell migration in preclinical work, so this blend stacks that theoretical concern more than any other here.
KPV has no human safety data of any kind.
Combinations
Running components together makes attribution impossible in both directions. If something improves you cannot tell which component did it, and if something goes wrong you cannot tell which one to stop. Blends are convenient and they are also the format that teaches you least about your own response.
Four components is where this stops being a theoretical objection. If you develop a reaction to this blend you have four candidates and no way to test between them without buying everything separately anyway.
Research status
Each component has its own literature, described in its own entry. The strongest is GHK-Cu topically; the weakest is KPV, which has no human data.
The combination has none.
Legal status
None of the components is approved as an injectable drug in any jurisdiction. GHK-Cu is permitted as a cosmetic ingredient. Sold for research use only.
WADA status
PROHIBITED. TB-500 is explicitly prohibited at all times under WADA class S2, which makes the blend prohibited regardless of the other components.
Conclusion
Klow is the most-combined product in this library and the least interpretable. Four compounds, one of which has no human data at all, two of which have their evidence on routes this blend does not use.
Convenience is the honest argument for it. There is no evidence argument.
Sources
Track your own Klow Blend protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.